9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation
Additional analyses to determine if a subgroup of patients and/or symptoms may have been responsive to treatmentCompany remains on track to deliver vurolenatide Phase 2 short bowel syndrome results by end of monthRALEIGH, NC / ACCESSWIRE / June 21, 2022 / 9 Meters Biopharma, Inc.
The copyright of this article belongs to the original author/organization.
The current content only represents the author’s point of view, and has nothing to do with the position of Longbridge. The content is for investment reference only and does not constitute any investment advice. If you have any questions or suggestions about the content services provided by Longbridge, please contact: firstname.lastname@example.org